If you would like to learn more about future focusIR related events and roundtables, please submit your details here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksImperial Innovations Group Regulatory News (IVO)

  • There is currently no data for IVO

EPS Licensing Deal

9 Nov 2007 09:00

Imperial Innovations Group plc09 November 2007 9 November 2007 Licensing of Intellectual Property to Edinburgh Petroleum Services Imperial Innovations Group plc (AIM: IVO), today announces that it has licensedto Edinburgh Petroleum Services Ltd (EPS), a subsidiary of WeatherfordInternational Ltd., the Deconvolution algorithm software developed by ProfessorAlain Gringarten, the Chair of Petroleum Engineering at Imperial College and aworld authority on well testing analysis, and Dr Thomas von Schroeter, an expertin signal processing at the Department of Earth Sciences at Imperial CollegeLondon. Software containing complex mathematical algorithms is used extensively by theoil and gas exploration and production (E&P) industry to analyse data andresults gathered from tests on appraisal oil wells. Recent improvements in welltest efficiency to minimise the amount of oil that is burnt off during the testprocess, have altered test output data. This has created a need for new dataanalysis techniques. The Deconvolution algorithm software provides a key answerto this need for accurate data analysis and interpretation. EPS will use the Deconvolution algorithm software as part of its EPS PanSystem(R) software package, a product used extensively in the E&P industry foranalysing the results of well testing. Susan Searle, CEO Imperial Innovations said, "This new software developed byworld class inventors at Imperial College and licensed to Weatherford shouldsignificantly improve the efficiency of the well testing process," "We wanted to get the best deconvolution algorithm both for PanSystem clientsand to analyse data from our optical pressure, temperature and flow sensors,"commented Laurence Ormerod, VP Solutions Architecture for Weatherford. "It wasclear to us that Imperial had the right expertise for our needs." . -Ends- For more information contact: Imperial InnovationsSusan Searle, Chief Executive Officer +44 (0)20 7594 6591Lucy Ahfong, Marketing Communications Executive +44 (0)20 7594 6644 M:CommunicationsPatrick d'Ancona / Eleanor Williamson +44 (0)20 7153 1539 JP Morgan Cazenove (NOMAD to Imperial Innovations)Steve Baldwin +44(0)20 7588 2828 Notes to Editors About Imperial InnovationsImperial Innovations is one of the UK's leading technology transfer andcommercialisation companies. The company was founded in 1986 and its ordinaryshares admitted to trading on the AIM Market of London Stock Exchange plc inJuly 2006, raising £25 million at an offer price of 365p and £1 million by meansof a public offer. The company's integrated approach encompasses the identification of ideas,protection of intellectual property, development and licensing of technology andformation, incubation and investment in technology businesses. A wide range oftechnologies are commercialised within the areas of healthcare, energy,environment and emerging technology trends. Based at Imperial College London, the company has established equity holdings in74 technology businesses and is managing 133 commercial agreements as of 31 July2007. Imperial Innovations also commercialises technologies originating fromoutside Imperial College through incubation contracts with the Carbon Trust andWRAP and has commercialisation contracts with a number of multinationalcorporations including BAE Systems. www.imperialinnovations.co.uk About Weatherford Weatherford is one of the largest global providers of innovative mechanicalsolutions, technology and services for the drilling and production sectors ofthe oil and gas industry. Weatherford operates in over 100 countries and employsmore than 35,000 people worldwide. www.weatherford.com This information is provided by RNS The company news service from the London Stock Exchange
Date   Source Headline
5th Sep 20162:40 pmRNSHolding(s) in Company
24th Aug 20167:01 amRNSCell Medica and UCL collaboration
12th Jul 20167:02 amRNSCell Medica acquires Delenex Therapeutics
6th Jul 20167:00 amRNSEconic raises £5m to develop novel catalyst tech
30th Jun 201612:11 pmRNSPsiOxus and Bristol-Myers Squibb collaboration
28th Jun 20167:00 amRNSStorm Therapeutics raises £12m
21st Jun 20164:35 pmRNSPrice Monitoring Extension
21st Jun 20167:00 amRNSDirector's share purchase
20th Jun 20167:03 amRNSCircassia cat allergy Phase III study
17th Jun 20167:00 amRNSCell Medica and Baylor College of Medicine partner
16th Jun 201610:44 amRNSReplacement Holding(s) in Company
14th Jun 20163:20 pmRNSEdison issues outlook on Imperial Innovations)
14th Jun 20169:00 amRNSHolding(s) in Company
13th Jun 20167:00 amRNSAllotment of Deferred Placing Shares
31st May 20167:00 amRNSFeaturespace closes £6.2 million funding round
26th May 20167:00 amRNS£3 million funding round for Inflowmatix
11th May 201612:32 pmRNSDavid Newlands appointed Chairman
4th May 20164:35 pmRNSPrice Monitoring Extension
4th May 201611:08 amRNSNexeon raises £30m, plans development lab in Asia
4th May 20167:00 amRNSAnalyst and Investor day
29th Apr 20164:35 pmRNSPrice Monitoring Extension
29th Apr 201612:42 pmRNSSale of Innovations portfolio Stanmore Implants
7th Apr 20167:00 amRNSHalf Yearly Report
21st Mar 20167:00 amRNSDr Martin Knight to step down from the board
18th Mar 201612:40 pmRNSNotice of Results
17th Mar 20167:00 amRNSTopiVert reports successful Phase I clinical study
26th Feb 20168:39 amRNSHolding(s) in Company
25th Feb 20163:59 pmRNSHolding(s) in Company
25th Feb 20163:50 pmRNSHolding(s) in Company
25th Feb 20168:53 amRNSHolding(s) in Company
22nd Feb 20165:01 pmRNSAdmission of shares to trading on AIM
22nd Feb 201612:29 pmRNSResult of General Meeting
22nd Feb 20167:00 amRNS£13.5m funding round in Precision Ocular
11th Feb 20162:51 pmRNSHolding(s) in Company
8th Feb 20167:00 amRNSInnovations leads £5m Series A round in Aqdot
4th Feb 20166:08 pmRNSResult of Placing
4th Feb 20167:00 amRNSPlacing to raise £100 million
2nd Feb 20167:00 amRNSMISSION Therapeutics raises £60 million
26th Jan 20167:00 amRNSInivata completes £31.5m Series A funding round
25th Jan 20167:00 amRNSInnovations joins Apollo consortium
18th Jan 20167:00 amRNSInnovations invests £25m in new £50m UCL Tech Fund
2nd Dec 20157:00 amRNSKesios Therapeutics raises £19 million
19th Nov 20151:51 pmRNSResult of AGM
4th Nov 20151:40 pmRNSGrant of share options
28th Oct 20157:00 amRNSPosting of Annual Report and Notice of AGM
22nd Oct 20157:00 amRNSLeads £1.5m seed funding into AI pioneer, Telectic
14th Oct 20157:00 amRNSFinal Results
22nd Sep 20154:10 pmRNSNotice of Results
12th Aug 20157:00 amRNSIssue of Equity
4th Aug 20157:01 amRNS£2.5m funding round in Oxford Biotrans

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.